Ny

Ar det farligt att gora Gastric bypass?

Är det farligt att göra Gastric bypass?

Du bör känna till att det finns biverkningar och risker med metoden. En specifik komplikation vid Gastric bypass är läckage vid den nya kopplingen mellan tunntarm och magsäck. Cirka 0–2 % av patienterna drabbas av detta. Efter ingreppet kan brist på B12, folsyra, järn, kalk och D‑vitamin uppkomma.

Hur lång tid tar en Gastric bypass operation?

Smärtlindring vid hemkomst Värk och smärta från operationsområdet brukar kännas cirka en vecka efter operationen för att sedan avta. Värk från axlar kan sitta i upp till några veckor efter operationen.

How effective is gastric bypass surgery for Helicobacter pylori?

EFFECT OF H. PYLORI INFECTION ON BARIATRIC SURGERY OUTCOMES. The majority of the studies, focused on standard laparoscopic Roux-en-Y gastric bypass (LRYGB) outcomes, have reported a reduced prevalence of postsurgical lesions after successful H. pylori eradication.

What is the best treatment for pylori and bariatric surgery?

H. PYLORI AND BARIATRIC SURGERY. An increase in the eradication treatment efficacy can be obtained by extending the treatment period [ 61 ]. A recent trial, aimed to compare 7- and 14-d first-line treatment with clarithromycin-based triple therapy in obese patients, showed that the latter is more effective [ 62 ].

Should we eradicate Helicobacter pylori infection in obese patients with lrygb?

If the management of H. pyloriinfection in obese patients who are candidates for bariatric surgery is still controversial, there are plausible reasons to attempt eradication in H. pylori-positive patients, particularly in those undergoing LRYGB in whom a large part of the stomach is inaccessible to upper endoscopy after surgery.

How common is Helicobacter pylori infection?

Helicobacter pylori(H. pylori) is one of the most common human infections and it is estimated that more than half of the world population is infected[1]. H. pyloriis an ancient colonizer of the human stomach and represents the main etiological factor in the development of gastritis, peptic ulcer and gastric malignant lesions.

Share this post